$3.70
+0.31 (+9.14%)
Open$3.59
Previous Close$3.39
Day High$3.84
Day Low$3.52
52W High$33.68
52W Low$2.68
Volume—
Avg Volume1.37M
Market Cap177.04M
P/E Ratio—
EPS$-2.89
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+567.0% upside
Current
$3.70
$3.70
Target
$24.68
$24.68
$18.50
$24.68 avg
$35.72
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.92M | 2.20M | 177.59M |
| Net Income | -146,901,622 | -99,377,224 | -3,219,143 |
| Profit Margin | -5,026.0% | -4,774.7% | -1.8% |
| EBITDA | -164,037,203 | -117,134,202 | -5,179,349 |
| Free Cash Flow | — | — | -3,332,995 |
| Rev Growth | +33.0% | +33.0% | -5.8% |
| Debt/Equity | — | — | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |